Abstract: A non-road mobile machinery (NRMM) is provided and includes a fuel storage device, a fuel supply device, a vapor adsorption device, and an engine body. The vapor adsorption device is provided with an air vent communicated to the atmosphere. A vapor discharge hole of the fuel storage device is communicated to an adsorption vent of the vapor adsorption device. The NRMM also includes a valve mechanism connected between a desorption vent of the vapor adsorption device and an intake channel of the engine body. The valve mechanism is conducted with the working of the engine body and blocked with the stop of the engine body. The NRMN improves the evaporation emission performance of the NRMM when compared to the prior art and solves the problem that the evaporation emissions of the NRMM in the prior art are prone to exceed the standard.

Abstract: The present application relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable salt thereof. The present application relates to use of the compound and the composition in the prevention or treatment of diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system. The present application also provides a method for preventing and/or treating arginine vasopressin-related diseases.

Abstract: The present invention provides aqueous ophthalmic formulations containing 0.01%-5% by weight of cyclosporine which exists in the form of micelles having a particle size not greater than 20 nm, and methods of making and using such formulations.

Abstract: A heat dissipation system for a high-speed train running in a low-vacuum tube is provided. Component groups that provide power and resistance for the movement and stop of a train are provided at a periphery, close to the train, in a low-vacuum tube. The component group is provided with a group A cooling assembly. The group A cooling assembly includes a group A cooling-type heat exchanger and/or a group A nozzle assembly attached to the back of the component group. Since the friction between the train running at high speed and the air in the low-vacuum tube and the operation of the key equipment in the low-vacuum tube will generate a lot of heat, the group A cooling assembly in the component group in the low-vacuum tube exchanges the heat with the air in the low-vacuum tube.

Abstract: The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Abstract: Provided herein are stable formulations that deliver one or more neuroactive steroid anesthetic agents in a micellar carrier or self-emulsifying system, which formulations are particularly suitable for use as intravenous anesthetics.

Abstract: The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Abstract: The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Abstract: Nanoparticles and microspheres are provided for delivering an anticancer agent or other active agents to a subject. The nanoparticles and the microspheres are formed from a core that is encased by a coating or shell that includes a somatostatin-albumin fusion protein or analogue thereof. The somatostatin-albumin fusion protein includes at least one albumin (or an analog thereof) moiety, at least one somatostatin moiety (e.g. SST-14, SST-28), and at least one spacer connecting albumin to albumin, somatostatin to somatostatin and/or albumin to somatostatin moieties.

Abstract: The present invention relates to a pre-filled syringe containing Moxifloxacin has a plunger, a barrel, a needle with gauge, kits having this syringe and the use of the syringe for the administration of Moxifloxacin for postsurgical bacterial endophthalmitis after cataract surgery.

Abstract: This present disclosure discloses a bioadhesive boric acid formulation and its use and preparation method. Specifically, a preferred vaginal bioadhesive boric acid formulation mainly comprises of: methylparaben, propylparaben, potassium sorbate, chitosan, glycerin, carbopol 974, polycarbophil, boric acid, and purified water. The vaginal boric acid preparation are capable of retaining and releasing boric acid in the vagina. It is proved experimentally that boric acid acts as an antibacterial component of this gel and can be maintained at a relatively high concentration in vaginal fluid. Further, it is demonstrated that the vaginal bioadhesive boric acid formulation has a dynamic viscosity >100000 cps, pH value of 2-5, good moisture retention capability. The formulation is non-allergenic, non-vaginal irritation, and capable of inhibiting bacteria and fungi.

Abstract: The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Abstract: This invention discloses a bioadhesive boric acid formulation and its preparation method. Specifically, preferred vaginal bioadhesive boric acid formulation mainly comprises chitosan, carbopol 974 , polycarbophil, boric acid, and purified water as a gel. The main performance characteristic of this vaginal boric acid preparation is the ability of the formulation to retain and release boric acid in the vagina by using a combination of carbopol 974 and polycarbophil as preferred bioadhesive polymers. It was proved experimentally that boric acid as the antibacterial component of this gel can be maintained at a relatively high concentration (>10 mg/mL) in vagina for an extended period of time (>2 hours) with the use of a combination of polyacrylic acid polymers, i.e. carbopol 974 and polycarbophil.

Abstract: A topical composition comprising a substituted resorcinol and a solid powder having a particle size distribution width of at least 15 microns is provided. Methods of treating the skin are also provided.

Abstract: Flexible film or strip dosing device and method for various therapeutic applications are disclosed. The device includes at least one film or strip and a packaging container for the film or strip. The film or strip normally include a polymer base with or without a therapeutic agent admixed with the polymer base. The film or strip is printed with doses, marks or calibrated lines to indicate different length of the film and therefore the different doses of the therapeutic agents. The packaging container or dispenser can have marks or calibrated lines similar to a ruler which measures the length of film and therefore the different doses of therapeutic agents. The packaging container may have a built-in cutter to conveniently cut the film or strips as needed for flexible dosing of therapeutic agents.